AI Article Synopsis

Article Abstract

Background: Insurance may lengthen or inhibit time to follow-up after positive screening mammography. We assessed the association between insurance status and time to initial diagnostic follow-up after a positive screening mammogram.

Methods: Using 1995-2010 data from a North Carolina population-based registry of breast imaging and cancer outcomes, we identified women with a positive screening mammogram. We compared receipt of follow-up within 60 days of screening using logistic regression and evaluated time to follow-up initiation using Cox proportional hazards regression.

Results: Among 43,026 women included in the study, 73% were <65 years and 27% were 65+ years. Median time until initial diagnostic follow-up was similar by age group and insurance status. In the adjusted model for women <65, uninsured women experienced a longer time to initiation of diagnostic follow-up [HR, 0.47; 95% confidence interval (CI), 0.25-0.89] versus women with private insurance. There were increased odds of these uninsured women not meeting the Centers for Disease Control and Prevention guideline for follow-up within 60 days (OR, 1.59; 95% CI, 1.31-1.94). Among women ages 65+, women with private insurance experienced a faster time to follow-up (adjusted HR, 2.09; 95% CI, 1.27-3.44) than women with Medicare and private insurance. Approximately 10% of women had no follow-up by 365 days.

Conclusions: We found differences in time to initial diagnostic follow-up after a positive screening mammogram by insurance status and age group. Uninsured women younger than 65 years at a positive screening event had delayed follow-up.

Impact: Replication of these findings and examination of their clinical significance warrant additional investigation. Cancer Epidemiol Biomarkers Prev; 25(11); 1474-82. ©2016 AACR.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5115635PMC
http://dx.doi.org/10.1158/1055-9965.EPI-16-0148DOI Listing

Publication Analysis

Top Keywords

positive screening
16
follow-up positive
12
diagnostic follow-up
8
screening mammography
8
time follow-up
8
follow-up
5
screening
5
insurance-based differences
4
time
4
differences time
4

Similar Publications

18F-Sodium Fluoride PET/CT as a Tool to Assess Enthesopathies in X-Linked Hypophosphatemia.

Calcif Tissue Int

January 2025

Endocrinology Department, School of Medicine, Pontificia Universidad Católica de Chile, Av. Diagonal Paraguay 262, Cuarto Piso, Santiago, Chile.

X-linked hypophosphatemia (XLH) is a rare metabolic disorder characterized by elevated FGF23 and chronic hypophosphatemia, leading to impaired skeletal mineralization and enthesopathies that are associated with pain, stiffness, and diminished quality of life. The natural history of enthesopathies in XLH remains poorly defined, partly due to absence of a sensitive quantitative tool for assessment and monitoring. This study investigates the utility of 18F-NaF PET/CT scans in characterizing enthesopathies in XLH subjects.

View Article and Find Full Text PDF

Experiences of patients who retest positive for SARS-CoV-2 Omicron variant after discharge: a qualitative study.

J Infect Dev Ctries

December 2024

The Cancer Hospital Affiliated to Shandong First Medical University (Shandong Cancer Prevention Research Institute, Shandong Cancer Hospital), Jinan 250117, China.

Introduction: In this study, we analyzed the psychological aspects of coronavirus disease 2019 (COVID-19) patients who were discharged from the hospitals in Shanghai, China, and later had positive nucleic acid retest results for the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant infection (re-positive COVID-19). The purpose was to gain clarity on the patients' needs and to provide evidence for the medical staff to deliver scientific and targeted health care to the patients.

Methodology: We screened patients who tested positive for SARS-CoV-2 Omicron variant infection by nucleic acid testing after having previously recovered from a COVID-19 infection and being discharged from Shanghai shelter hospitals or COVID-19-designated hospitals from April 3, 2022, to May 10, 2022.

View Article and Find Full Text PDF

Nevoid basal cell carcinoma syndrome (Gorlin syndrome): a case report.

J Med Case Rep

January 2025

Department of Dermatology and Venereology, Faculty of Medicine, University of Aleppo, Aleppo, Syria.

Background: Basal cell nevus syndrome, also known as Gorlin or Gorlin-Goltz syndrome, is a hereditary condition caused by mutation in the PATCHED gene. The syndrome presents with a wide range of clinical manifestations, including basal cell carcinomas, jaw cysts, and skeletal anomalies. Diagnosis is based on specific criteria, and treatment typically includes surgical removal of basal cell carcinomas.

View Article and Find Full Text PDF

Purpose: Prior sperm DNA fragmentation index (DFI) thresholds for diagnosing male infertility and predicting assisted reproduction technology (ART) outcomes fluctuated between 15 and 30%, with no agreed standard. This study aimed to evaluate the impact of the sperm DFI on early embryonic development during ART treatments and establish appropriate DFI cut-off values.

Methods: Retrospectively analyzed 913 couple's ART cycles from 2021 to 2022, encompassing 1,476 IVF and 295 ICSI cycles, following strict criteria.

View Article and Find Full Text PDF

Guillain-Barré syndrome following falciparum malaria infection: a case report.

BMC Neurol

January 2025

Department of Radiology, School of Medicine, College of Medicine and Health Sciences, Mizan-Tepi University, Mizan-Teferi, Ethiopia.

Background: Malaria is an infectious disease caused by Plasmodium parasites, transmitted to humans by infected female Anopheles mosquitoes. Five Plasmodium species infect humans: P. vivax, P.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!